Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.

<h4>Objective</h4>To identify comorbidity indices that have been validated in cancer populations, with a focus on breast cancer and human epidermal growth factor receptor-2-positive (HER2+) breast cancer.<h4>Study design and setting</h4>A systematic review of the literature o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maribel Salas, Mackenzie Henderson, Meera Sundararajan, Nora Tu, Zahidul Islam, Mina Ebeid, Laura Horne
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/07cd539080644ac4bd6e1fa68efb2d31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07cd539080644ac4bd6e1fa68efb2d31
record_format	dspace
spelling	oai:doaj.org-article:07cd539080644ac4bd6e1fa68efb2d312021-12-02T20:07:05ZUse of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.1932-620310.1371/journal.pone.0252925https://doaj.org/article/07cd539080644ac4bd6e1fa68efb2d312021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252925https://doaj.org/toc/1932-6203<h4>Objective</h4>To identify comorbidity indices that have been validated in cancer populations, with a focus on breast cancer and human epidermal growth factor receptor-2-positive (HER2+) breast cancer.<h4>Study design and setting</h4>A systematic review of the literature on the use of comorbidity indices in any cancer, breast cancer, and HER2+ breast cancer using Ovid and PubMed.<h4>Results</h4>The final data set comprised 252 articles (252 any cancer, 39 breast cancer, 7 HER2+ breast cancer). The most common cancers assessed were hematologic and breast, and the most common comorbidity index used was the Charlson Comorbidity Index (CCI) or a CCI derivative. Most validity testing of comorbidity indices used predictive validity based on survival outcomes. Hazard ratios for survival outcomes generally found that a higher comorbidity burden (measured by CCI) increased mortality risk in patients with breast cancer. All breast-cancer studies that validated comorbidity indices used CCI-based indices. Only one article validated a comorbidity index in HER2+ breast cancer.<h4>Conclusion</h4>CCI-based indices are the most appropriate indices to use in the general breast-cancer population. There is insufficient validation of any comorbidity index in HER2+ breast cancer to provide a recommendation, indicating a future need to validate these instruments in this population.Maribel SalasMackenzie HendersonMeera SundararajanNora TuZahidul IslamMina EbeidLaura HornePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0252925 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maribel Salas Mackenzie Henderson Meera Sundararajan Nora Tu Zahidul Islam Mina Ebeid Laura Horne Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
description	<h4>Objective</h4>To identify comorbidity indices that have been validated in cancer populations, with a focus on breast cancer and human epidermal growth factor receptor-2-positive (HER2+) breast cancer.<h4>Study design and setting</h4>A systematic review of the literature on the use of comorbidity indices in any cancer, breast cancer, and HER2+ breast cancer using Ovid and PubMed.<h4>Results</h4>The final data set comprised 252 articles (252 any cancer, 39 breast cancer, 7 HER2+ breast cancer). The most common cancers assessed were hematologic and breast, and the most common comorbidity index used was the Charlson Comorbidity Index (CCI) or a CCI derivative. Most validity testing of comorbidity indices used predictive validity based on survival outcomes. Hazard ratios for survival outcomes generally found that a higher comorbidity burden (measured by CCI) increased mortality risk in patients with breast cancer. All breast-cancer studies that validated comorbidity indices used CCI-based indices. Only one article validated a comorbidity index in HER2+ breast cancer.<h4>Conclusion</h4>CCI-based indices are the most appropriate indices to use in the general breast-cancer population. There is insufficient validation of any comorbidity index in HER2+ breast cancer to provide a recommendation, indicating a future need to validate these instruments in this population.
format	article
author	Maribel Salas Mackenzie Henderson Meera Sundararajan Nora Tu Zahidul Islam Mina Ebeid Laura Horne
author_facet	Maribel Salas Mackenzie Henderson Meera Sundararajan Nora Tu Zahidul Islam Mina Ebeid Laura Horne
author_sort	Maribel Salas
title	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
title_short	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
title_full	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
title_fullStr	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
title_full_unstemmed	Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
title_sort	use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: a systematic review.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/07cd539080644ac4bd6e1fa68efb2d31
work_keys_str_mv	AT maribelsalas useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT mackenziehenderson useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT meerasundararajan useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT noratu useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT zahidulislam useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT minaebeid useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview AT laurahorne useofcomorbidityindicesinpatientswithanycancerbreastcancerandhumanepidermalgrowthfactorreceptor2positivebreastcancerasystematicreview
_version_	1718375282226757632

Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.

Ejemplares similares